Drug Metabolism and Bioanalysis Letters (DMBL)

Drug Metabolism and Bioanalysis Letters is a specialized scientific journal that provides a targeted platform for high‑impact research and scholarly dialogue on drug metabolism and bioanalytical science. Established in 2022 under the Bentham Science Publishers portfolio, the journal contributes to understanding the molecular, cellular, and systemic processes that determine drug fate in organisms — and the analytical methods used to measure and characterize those processes. Published on a half‑yearly basis, this interdisciplinary journal bridges pharmacology, biochemistry, analytical chemistry, and pharmaceutical sciences by featuring letters, original research articles, systematic and mini‑reviews, and themed contributions on topics such as cytochrome P450 enzyme systems, drug‑drug interactions, extrahepatic metabolism, toxicokinetics, and cutting‑edge bioanalytical techniques (e.g., LC/MS and separation sciences). Its content helps researchers and clinicians optimize therapeutic regimens by characterizing drug absorption, distribution, metabolism, and elimination pathways, as well as predictive models for human and animal studies. In addition to methodological advances, the journal emphasizes translational aspects — including therapeutic drug monitoring, biomarker assay development, and diagnostic assay innovations — supporting professionals involved in drug discovery, clinical pharmacology, toxicology, and regulatory science. With a CiteScore of ~2.9 and indexing in major databases, Drug Metabolism and Bioanalysis Letters fosters rapid dissemination of research that informs both academic inquiry and practical applications in pharmaceutical and life sciences.

Drug Metabolism and Bioanalysis Letters (DMBL) is :-

• International, Peer-Reviewed, Open Access, Refereed, Drug guides, Drug metabolism mechanisms, Pharmacokinetics & toxicokinetics, Drug‑drug and drug‑food interactions, Bioanalysis technologies such as LC/MS, chromatography, Applications in therapeutic drug monitoring, biomarker assays, diagnostic studies. , Online or Print , Half-Yearly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 2949-6810, E-ISSN: 2949-6829, Established: 2022,
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE